Engflag

Ialugen plus

Quick links to important sections

Ialugen plus

Ialugen plus_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ialugen plus

The medicine Ialugen plus is a topical combination drug used in dermatology, characterized by its dual-action formulation for managing skin injuries where both infection control and active tissue repair are necessary. This pharmaceutical entity, developed by IBSA Institut Biochimique SA, is available as a cream or a medicated compress and is broadly classified as an antiseptic cicatrizing agent.

Quick Facts Overview

Property Description
Active Ingredients Sodium Hyaluronate, Sulfadiazine Silver
Form Cream, Medicated Compress
Pharmacological Class Dermatological Preparation, Topical Anti-infective, Wound Healing Agent
Route Topical (Cutaneous)
Origin Semi-synthetic (Biopolymer/Synthetic Antimicrobial)

Defining Identity and Composition

Ialugen plus contains two primary active ingredients with complementary roles: Sodium Hyaluronate and Sulfadiazine Silver. Sodium Hyaluronate, a form of hyaluronic acid, supports the essential structural components needed for tissue regeneration. Sulfadiazine Silver is an antimicrobial agent classified as a topical sulfa antibiotic. This combination is clinically recognized for its comprehensive efficacy in supporting the healing of various skin lesions, including minor burns and small infected wounds.

General Therapeutic Purpose

The overall purpose of Ialugen plus is to create optimal therapeutic conditions for the recovery and closure of damaged skin. Its inherent dual mechanism is designed to actively promote epithelialization and accelerate the natural process of scarring, while the antimicrobial component ensures proactive infection prophylaxis. Pharmacological studies have supported the role of Sodium Hyaluronate in optimizing the tissue recovery process by supporting cell migration and division at the site of injury. This combination is particularly beneficial in scenarios where initial wound healing needs protection from the onset of microbial colonization, allowing the underlying repair processes to proceed effectively toward the restoration of the skin barrier function.

What side effects are possible with Ialugen plus?

Possible Side Effects and Safety Information

The official safety profile for Ialugen plus is structured around the potential adverse reactions associated with its components, particularly the topical sulfonamide, Sulfadiazine Silver. The most common effects are Dermatological Reactions occurring at the application site. These include a burning sensation, pain, itching, and the formation of a rash.

A specifically documented local effect is skin discoloration, which may manifest as a brownish-gray or black appearance in the treated area. The possibility of photosensitivity, an increased sensitivity to light, is also noted in regulatory documentation.

Systemic Risk and Serious Adverse Reactions

When the medicine is applied to large areas or used for prolonged periods, the risk of systemic absorption of the sulfonamide component increases. This potential exposure raises concerns for the Blood and Lymphatic System, including the documented risk of leukopenia (a decrease in white blood cell count) and, rarely, severe blood disorders like aplastic anemia.

A specific Time-Related Pattern is documented for leukopenia, which typically reaches its peak depression within two to four days following treatment initiation. Serious, though rare, Hypersensitivity Reactions associated with sulfonamides include Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Population-Specific Safety Constraints

Official labeling includes explicit constraints for specific patient populations. The medicine is Contraindicated for use in newborns and infants under two months of age due to the serious risk of kernicterus. Caution is also advised when treating individuals with severe hepatic or renal impairment due to the risk of drug accumulation, and for those with G6PD deficiency due to the potential for hemolysis.

This structure ensures the risk profile, balancing common local effects with documented systemic and severe risks, is communicated according to government regulatory standards.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose or high systemic exposure to Ialugen plus is associated with the Sulfadiazine Silver component, particularly when the product is applied to extensive skin areas or following accidental ingestion. The manifestations reflect the potential for systemic sulfonamide toxicity, as described in regulatory documents.

Documented Overdose Manifestations and Outcomes

Official labeling documents symptoms arising from systemic exposure, which can include hematological effects (such as leukopenia and thrombocytopenia), renal failure, and toxic hepatitis.

Severe, potentially life-threatening outcomes mentioned in regulatory profiles include serious cutaneous reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Required Emergency Actions

The most important immediate action is to interrupt the use of all silver-containing products. If accidental ingestion occurs or if any symptoms of a severe reaction or organ damage are observed, immediate medical attention must be sought.

Overdose Management and Monitoring

Management is based on symptomatic and supportive care. Regulatory documents note that Sulfadiazine is dialyzable. Monitoring of blood count and renal function is required in cases of significant systemic absorption. No specific antidote is officially documented.

Population-Specific Warning

The product is strictly contraindicated for use in premature babies and infants up to two months of age due to the risk of Kernicterus, a severe neurological complication associated with the systemic absorption of sulfonamides.

Therapeutic Uses of Ialugen plus

What Ialugen Plus Treats: Main Uses and Benefits

Ialugen Plus is a topical treatment that is commonly used for easing symptoms associated with damaged skin that involve systemic or localized discomfort. The support provided is related to the ingredients. The primary role of Ialugen Plus is to support the management of symptoms associated with damaged skin. The product's combination of ingredients is commonly used across a wide therapeutic area. The primary indication is for conditions presenting with systemic or localized discomfort, such as infected burns, chronic wounds, and skin lesions.

Key Areas of Symptom Management

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, often used during phases when symptoms become more noticeable.

  • Relief from Acute Symptom Clusters (Discomfort & Irritation): This medication is relevant for easing symptoms related to inflammatory or irritative states. This supports the patient during difficult episodes by easing distress associated with these symptoms.

    Quick Fact: Used for symptoms of inflammatory or irritative states

  • Support for Functional Strain and Tension (Stability & Comfort): The product may assist with maintaining functional stability of the affected area. It contributes to easing the overall symptom load in conditions where functional stability becomes affected. This assists with maintaining functional stability during phases when symptoms become more noticeable.

Eligibility and Restrictions for Use

The eligibility profile for Ialugen plus is defined by two primary, absolute constraints established in official regulatory documentation: age and known hypersensitivity.

Populations That Must NOT Use This Medicine (Contraindications)

Classification Eligible Population Ineligible Population (Contraindication)
Age Profile Patients at or over the age of one month. Children under the age of one month (newborns).
Hypersensitivity Individuals without known allergies to the product's components. Individuals with a known hypersensitivity or allergic reaction to the active substances (Sodium Hyaluronate or Silver Sulfadiazine) or to any of the excipients (inactive ingredients).

Individuals who are known to be allergic to any component of the product are formally contraindicated, meaning use is prohibited due to the risk of an allergic reaction.

Special Considerations

The eligibility status for use during pregnancy and lactation has not been established through systematic scientific investigations. Therefore, official regulatory information advises consulting a healthcare professional before use in these physiological states. This is a restricted eligibility status, not a formal contraindication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Ialugen plus is defined by potential systemic effects arising from the absorbed sulfadiazine component and local incompatibilities caused by the silver component, as documented in regulatory information. All interaction statements refer to officially documented patterns only.

Interaction Scope

Category Official Regulatory Information
Specific Interacting Medicines Phenytoin, Cimetidine.
Interaction Mechanism Alteration of systemic exposure (increased plasma concentration/potentiated effect) of co-administered drugs due to displacement or metabolic inhibition by the absorbed sulfadiazine. Local Inactivation of enzymes by the silver component.
Interaction-Related Restrictions Co-administration with Topical Proteolytic Enzymes must be avoided due to the risk of inactivation. Potential for potentiated effects of Oral Anticoagulants is noted.
Population-Specific Notes Interaction risk is heightened in patients with hepatic or renal impairment due to the potential for reduced clearance of the absorbed sulfadiazine, which increases systemic interaction risk.

Official Interaction Statements

  • Co-administration with Phenytoin may result in increased systemic plasma concentrations of Phenytoin.
  • The medication may potentiate the effects of Oral Anticoagulants and Methotrexate.
  • Concurrent treatment with Cimetidine has been associated with an increased incidence of leukopenia.

The regulatory documents define the product's interaction structure based on the need to manage potential systemic pharmacokinetic interactions and local restrictions against using the product concurrently with topical proteolytic enzymes.

Mechanism of Action

Ialugen Plus operates through the distinct mechanisms of its two active components, Hyaluronic acid (HA) and Silver Sulfadiazine (SSD). HA is a large, negatively charged polysaccharide present as a major element in the extracellular matrix. It acts by binding numerous water molecules to form a viscous, highly hydrated physicochemical matrix at the application site. This matrix provides the local structural environment. SSD dissociates upon contact with the physiological environment, releasing the silver cation ( Ag^+). The Ag^+ cation interacts selectively with molecular groups found on the cell wall and plasma membrane of microbial organisms. This interaction disrupts the integrity of the microbial membrane and inactivates intracellular enzymes critical for metabolic function. This dual action modulates the physiological environment to favor defense and support the cellular processes necessary for localized tissue restructuring.

Dosage and Administration Information

Official Administration Instructions

Ialugen plus, a combination of sodium hyaluronate and silver sulfadiazine, is a topical preparation. The instructions focus on ensuring proper application to the affected area.

Route, Forms, and Frequency

Feature Instruction
Route of Administration Strictly Topical (external, cutaneous use)
Available Forms Cream and Medicated Compress/Gauze
Dosing Frequency Typically applied once or twice daily

Preparation and Application Protocol

  1. Wound Cleansing: The standard protocol involves ensuring the area to be treated is cleaned and, if necessary, debrided before each application to ensure the product is applied to a suitable wound bed.
  2. Application: The product, whether cream or compress, is applied directly to the lesion surface. The amount should be sufficient to completely cover the entire area being treated.
  3. Duration of Use: Treatment duration is not fixed. Application should be continued until the lesion is completely healed, as determined by the patient's healthcare provider.

Specific dose adjustments are not generally specified for older adults or those with renal or hepatic impairment due to the drug's topical route.

Recent Clinical Evidence

Recent Clinical Evidence for Ialugen Plus

Ialugen plus is a topical medication combining hyaluronic acid (HA) and silver sulfadiazine (SSD). Recent clinical evidence has focused on evaluating the synergistic effect of this fixed combination, particularly in comparison to silver sulfadiazine cream alone, for the treatment of various wounds.

Efficacy in Burns and Acute Wounds

Clinical studies, including randomized, controlled trials, have investigated the use of the HA-SSD combination for treating second-degree burns. Findings suggest that the fixed combination significantly reduces the time to complete re-epithelialization compared to SSD alone. For instance, in one multicenter study, patients treated with the HA-SSD formulation achieved complete healing several days faster than the group treated with SSD only. This accelerated healing is attributed to hyaluronic acid's role in promoting cell migration and division, which is crucial for tissue regeneration.

Impact on Chronic Wounds and Infection Control

Studies have also explored the effectiveness of the combined therapy in complicated chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and post-traumatic ulcers, which often involve bacterial contamination and delayed healing. The inclusion of silver sulfadiazine provides a broad-spectrum antimicrobial action against various bacteria and fungi, preventing or treating local infections. Research suggests that the combined action of HA and SSD is clinically effective in improving the wound healing process in these complex cases. The formulation aids in creating a favorable, moist environment for tissue repair, while the antiseptic component manages the bacterial load, which can otherwise impede granulation tissue formation and re-epithelialization.

Safety and Tolerability

In clinical evaluations, the fixed combination of hyaluronic acid and silver sulfadiazine has generally been found to be safe and well-tolerated at both the systemic and local levels. Adverse effects such as painful application or allergic reactions have been reported infrequently in the reviewed study populations.

Key Studies & References Hyaluronic acid derivatives and their healing effect on burns, epithelial surgical wounds, and chronic wounds: a systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Ialugen plus (FAQ)

Q: Where should I store this medication?

According to the official product information, this medication should be stored in its original, unopened container. It must be kept at controlled room temperature, which is between 20°C and 25°C (68°F and 77°F). The product information indicates that the medicine must be protected from moisture.

Q: Does this medicine make you sleepy?

Regulatory documents indicate that central nervous system (CNS) effects have been reported. These effects include somnolence (drowsiness), fatigue, and dizziness. Official label information advises users to be aware of how the medicine affects them before engaging in activities that require full attention.

How should Ialugen plus be stored and disposed of?

Storage Requirements

The official labeled storage conditions for Ialugen plus are designed to maintain the product's stability and effectiveness. The medicine must be kept at room temperature, typically defined as 15 C to 25 C, and stored protected from light.

Stability and Handling

  • Keep out of the sight and reach of children is a mandatory storage requirement.
  • The cream must not be used after the expiry date (EXP) printed on the packaging.
  • For the cream formulation, there is a specific in-use shelf-life: it must be used within 6 months after opening the tube. The screw-cap should be kept securely closed after each use.
  • Sterile medicated compresses are for single use only and must not be reused.

Disposal Instructions

To prevent environmental contamination, Ialugen plus must not be disposed of in household waste or wastewater. Expired or unused medicine must be returned to a pharmacist for safe and proper disposal as per regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagCzech Republic

flagEgypt

flagHungary

flagLebanon

flagSlovakia

flagSwitzerland

Equivalent of Ialugen plus found in:

A-Z Index: